Amphastar Pharmaceuticals, Inc. AMPH
We take great care to ensure that the data presented and summarized in this overview for Amphastar Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AMPH
View all-
Black Rock Inc. New York, NY5.94MShares$169 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.71MShares$77 Million0.0% of portfolio
-
Td Asset Management Inc1.84MShares$52.2 Million0.06% of portfolio
-
State Street Corp Boston, MA1.6MShares$45.3 Million0.0% of portfolio
-
Neuberger Berman Group LLC New York, NY1.37MShares$39 Million0.04% of portfolio
-
Pacer Advisors, Inc. Malvern, PA1.35MShares$38.3 Million0.12% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.2MShares$34 Million0.01% of portfolio
-
Fuller & Thaler Asset Management, Inc. San Mateo, CA1.13MShares$32.1 Million0.16% of portfolio
-
Epoch Investment Partners, Inc. New York, NY1.1MShares$31.2 Million0.21% of portfolio
-
Boston Trust Walden Corp979KShares$27.8 Million0.26% of portfolio
Latest Institutional Activity in AMPH
Top Purchases
Top Sells
About AMPH
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Insider Transactions at AMPH
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 17
2025
|
Rong Zhou SENIOR EVP, PRODUCTION CENTER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,967
-1.41%
|
$53,109
$27.69 P/Share
|
Mar 17
2025
|
Jack Y. Zhang CEO & CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Indirect |
7,223
-0.61%
|
$195,021
$27.69 P/Share
|
Mar 17
2025
|
Jack Y. Zhang CEO & CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
16,150
-0.61%
|
$436,050
$27.69 P/Share
|
Mar 17
2025
|
Yakob Liawatidewi EVP CORP ADMIN CENTER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,731
-1.87%
|
$46,737
$27.69 P/Share
|
Mar 17
2025
|
William J Peters CFO, EVP & TREASURER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,004
-2.34%
|
$81,108
$27.69 P/Share
|
Mar 15
2025
|
Rong Zhou SENIOR EVP, PRODUCTION CENTER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,222
-0.87%
|
$31,772
$26.66 P/Share
|
Mar 15
2025
|
Jack Y. Zhang CEO & CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Indirect |
4,115
-0.34%
|
$106,990
$26.66 P/Share
|
Mar 15
2025
|
Jack Y. Zhang CEO & CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
9,765
-0.37%
|
$253,890
$26.66 P/Share
|
Mar 15
2025
|
Yakob Liawatidewi EVP CORP ADMIN CENTER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,031
-1.1%
|
$26,806
$26.66 P/Share
|
Mar 15
2025
|
William J Peters CFO, EVP & TREASURER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,968
-1.51%
|
$51,168
$26.66 P/Share
|
Mar 14
2025
|
Jack Y. Zhang CEO & CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Indirect |
162,657
-11.96%
|
$4,229,082
$26.66 P/Share
|
Mar 14
2025
|
Jack Y. Zhang CEO & CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Indirect |
211,213
+13.45%
|
$2,956,982
$14.69 P/Share
|
Mar 14
2025
|
Jack Y. Zhang CEO & CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
226,285
-7.8%
|
$5,883,410
$26.66 P/Share
|
Mar 14
2025
|
Jack Y. Zhang CEO & CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
290,477
+9.1%
|
$4,066,678
$14.69 P/Share
|
Mar 10
2025
|
Rong Zhou SENIOR EVP, PRODUCTION CENTER |
BUY
Grant, award, or other acquisition
|
Direct |
24,692
+14.93%
|
-
|
Mar 10
2025
|
Yakob Liawatidewi EVP CORP ADMIN CENTER |
BUY
Grant, award, or other acquisition
|
Direct |
20,837
+18.2%
|
-
|
Mar 10
2025
|
William J Peters CFO, EVP & TREASURER |
BUY
Grant, award, or other acquisition
|
Direct |
36,747
+22.01%
|
-
|
Mar 10
2025
|
Jack Y. Zhang CEO & CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Indirect |
48,996
+4.09%
|
-
|
Mar 10
2025
|
Jack Y. Zhang CEO & CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
116,226
+4.26%
|
-
|
Mar 06
2025
|
Rong Zhou SENIOR EVP, PRODUCTION CENTER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,354
-1.15%
|
$37,912
$28.32 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 266K shares |
---|---|
Exercise of conversion of derivative security | 791K shares |
Open market or private sale | 100K shares |
---|---|
Payment of exercise price or tax liability | 468K shares |
Bona fide gift | 251K shares |